{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT01969357: Phase 2 Interventional Completed Type 2 Diabetes
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
SP-2086 H3PO4 (Retagliptin Phosphate), tetrahydro-imidazo[1,5-a] pyrazine
derivative, is a competitive DPP-4 inhibitor innovated in China under development by Jiangsu Hengrui Medicine for the treatment of Type 2 diabetes. In completed phase II trials, retagliptin monotherapy or in combination with metformin significantly decreased the HbA1c level in type 2 diabetic patients. Two phase III trials for retagliptin monotherapy aCnd in combination with metformin, respectively, were ongoing in China. Jiangsu Hengrui Medicine withdrew its application from the Chinese
FDA in April 2016 but is expected to refile the application.
Status:
Investigational
Source:
NCT00891241: Phase 1 Interventional Completed Heart Failure
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01107236: Phase 2 Interventional Completed Healthy
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01668147: Phase 1/Phase 2 Interventional Completed Drug Effects
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:diacetamate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Diacetamate (Acetaminophen Acetate, Acetaminophen Impurity, diacetyl-p-aminophenol) is a acetaminophen synthetic impurity. Acetaminophen-aspirin
mixtures have lower stability due to acetylation of the former
by the latter, producing diacetyl-p-aminophenol.
Status:
Investigational
Source:
INN:diampromide [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Diampromide is a synthetic narcotic analgesic. It was designed as a methadone analog and hence with a chiral center similar to that of the parent. Diampromide approximates to the potency of pethidine and morphine in mice and rats, respectively. It has been evaluated in postoperative pain. Diampromide is not found in any pharmaceutical preparations sold in the United States. It is under international control according to the UN Single Convention 1961 and its amendments, Schedule I.
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
Deximafen is antidepressant drug developed by Abbot Laboratories Inc.
Status:
Investigational
Source:
NCT01400477: Phase 2 Interventional Completed Schizophrenia
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
GTS-21 (also known as DMBX-A), a selective alpha-7 nicotinic acetylcholine receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. GTS-21 has been studied in Phase II in patients with schizophrenia and in patients with Alzheimer disease. However, these studies were discontinued. GTS-21 was also involved in phase II to reduce negative affect, improve cognition and/or reduce smoking relapse in healthy adult men and women who are chronic cigarette smokers. However, this study was withdrawn. Besides, GTS-21 has participated in phase II to investigate safety and efficacy in adults with attention-deficit hyperactivity disorder.
Status:
Investigational
Source:
INN:proheptazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Proheptazine is a substituted azacycloalkane patented by American Home Products Corp. as an opioid analgesic. Proheptazine produces similar effects to other opioids, including analgesia, sedation, euphoria, dizziness and nausea.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Amiglumide [CR 1795] is an amino acid derivative with cholecystokinin A antagonist activity. It has potential use for treating gastrointestinal disorders, pancreatitis and biliary dyskinesia. Amiglumide was developed in preclinical trials with Rottapharm in Italy.
